DelNS1-2019-nCoV-RBD-OPT
DelNS1-2019-nCoV-RBD-OPT is a COVID-19 vaccine candidate developed by Beijing Wantai Biological, Xiamen University and the University of Hong Kong.[2][3][4]
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Viral vector |
Clinical data | |
Trade names | Pneucolin |
Other names | DelNS1-nCoV-RBD LAIV[1] |
Routes of administration | Intranasal |
Part of a series on the |
COVID-19 pandemic |
---|
![]() Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom. |
|
Medical response |
|
![]() |
On 14 December 2022, the vaccine was listed by the National Health Commission of China as a secondary booster dose option for people who have completed their third doses of inactivated COVID-19 vaccines for 6 months or longer.[5]
References
- "A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19". clinicaltrials.gov. United States National Library of Medicine. 29 April 2021. Retrieved 3 May 2021.
- "China's nasal-spray COVID-19 vaccines undergoing clinical trials: official". Xinhua. 11 June 2021. Retrieved 10 July 2021.
- "A Phase I Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1)". chictr.org.cn. Chinese Clinical Trial Registry. Archived from the original on 7 April 2021. Retrieved 24 March 2021.
- "A Phase II Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1)". chictr.org.cn. Chinese Clinical Trial Registry. Archived from the original on 14 November 2020. Retrieved 24 March 2021.
- "关于印发新冠病毒疫苗第二剂次加强免疫接种实施方案的通知" (in Chinese). National Health Commission. 14 December 2022. Retrieved 14 December 2022.
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.